Clinicopathological characteristics of trials included in this study

Study	Trial phase	Underlying malignancy	No. of patients enrolled	Median age (range), year	Gender (Male/ Female)	Treatment	Median treatment duration (range), month	Median follow-up (range), month
Borghaei,2015 [6]	3	Lung cancer	292	61(37–84)	151/141	Nivolumab 3 mg/kg every 14 days	3.0(0.5–26.0)	> 13.2
Borghaei,2015 [6]	3	Lung cancer	290	64(21–85)	168/122	Docetaxel 75 mg/m2 every 21 days	3.0(0.8–17.3)	> 13.2
Brahmer, 2015 [7]	3	Lung cancer	135	62(39–85)	111/24	Nivolumab 3 mg/kg every 14 days	4.0(0.5–24.0)	< 11.0
Brahmer, 2015 [7]	3	Lung cancer	137	64(42–84)	97/40	Docetaxel 75 mg/m2 every 21 days	2.3(0.8–21.8)	< 11.0
Carbone, 2017 [8]	3	Lung cancer	271	63(32–89)	184/87	Nivolumab 3 mg/kg every 14 days	3.7(0–26.9)	13.5
Carbone, 2017 [8]	3	Lung cancer	270	65(29–87)	148/122	Chemotherapy once every 21 days	3.4(0–20.9)	13.5
Ferris, 2016 [10]	3	Head and neck cancer	240	59(29–83)	197/43	Nivolumab 3 mg/kg every 14 days	1.9	5.1(0–16.8)
Ferris, 2016 [10]	3	Head and neck cancer	121	61(28–78)	103/18	Systemic therapy single-agent	1.9	5.1(0–16.8)
Kang, 2017 [9]	3	G/GJC	330	62(54–69)	229/101	Nivolumab 3 mg/kg every 14 days	1.9	8.9
Kang, 2017 [9]	3	G/GJC	163	61(53–68)	119/44	Placebo 3 mg/kg every 14 days	1.9	8.6
Motzer, 2015 [11]	3	Renal cancer	410	62(23–88)	315/95	Nivolumab 3 mg/kg every 14 days	5.5(0–29.6)	> 14.0
Motzer, 2015 [11]	3	Renal cancer	411	62(18–86)	304/107	Everolimus 10 mg daily	3.7(0.2–25.7)	> 14.0
Robert, 2015 [12]	3	Melanoma	210	64(18–86)	121/89	Nivolumab 3 mg/kg every 14 days	NR	< 16.7
Robert, 2015 [12]	3	Melanoma	205	66(26–87)	125/83	Dacarbazine 1 g/m2 every 21 days	NR	< 16.7
Weber, 2017 [13]	3	Melanoma	453	56(19–83)	258/195	Nivolumab 3 mg/kg every 14 days	12.0	> 18.0
Weber, 2017 [13]	3	Melanoma	453	54(18–86)	269/184	Ipilimumab 10 mg/kg every 21 days	3.0	> 18.0
Wolchok, 2017 [14]	3	Melanoma	314	61(18–88)	206/108	Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 21 days	6	38
			316	60(25–90)	202/114	Nivolumab 3 mg/kg every 14 days	7.5	35.7
			315	62(18–89)	202/113	Ipilimumab 3 mg/kg every 21 days	3	18.6
D’angelo, 2018 [15]	2	Sarcoma	43	56(21–76)	22/21	Nivolumab 3 mg/kg every 14 days	2.3	13.6
D’angelo, 2018 [15]	2	Sarcoma	42	57(27–81)	19/23	Nivolumab 3 mg/kg + ipilimumab 1 mg/kg every 21 days	3.7	14.2
Long, 2018 [16]	2	Melanoma	35	59(53–68)	29/6	Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 21 days	NR	14.0
			25	63(52–74)	19/6	Nivolumab 3 mg/kg every 14 days	NR	17.0
			16	51(48–56)	11/5	Nivolumab 3 mg/kg every 14 days	NR	31.0
Motzer, 2015 [19]	2	Renal cancer	60	61	41/19	Nivolumab 0.3 mg/kg every 21 days	4.5(0–21.8)	> 24.0
			54	61	40/14	Nivolumab 2 mg/kg every 14 days	5.6(0.8–24.0)
			54	61	40/14	Nivolumab 10 mg/kg every 14 days	6.0(0.8–23.3)
Hamanishi, 2015 [18]	2	Ovarian cancer	20	60(47–79)	0/20	Nivolumab 1 or 3 mg/kg every 14 days	3.5(1.0–12.0)	11.0(3.0–32)
Hida, 2017 [29]	2	Lung cancer	35	65(31–85)	32/3	Nivolumab 3 mg/kg every 14 days	3.6(0.5–29.3)	< 30.0
Kudo, 2017 [30]	2	Esophageal cancer	65	62(49–80)	54/11	Nivolumab 3 mg/kg every 14 days	105(0.5–5.0)	10.8
Maruyama, 2017 [31]	2	Hodgkin lymphoma	17	63(29–83)	13/4	Nivolumab 3 mg/kg every 14 days	7.0(1.4–10.6)	9.8(6.0–11.1)
Nishio, 2017 [32]	2	Lung cancer	76	64(39–78)	49/27	Nivolumab 3 mg/kg every 14 days	NR	16.6(0.9–31.9)
Overman, 2017 [33]	2	Colorectal cancer	74	53(44–64)	44/30	Nivolumab 3 mg/kg every 14 days	11.0	12.0
Rizvi, 2015 [34]	2	Lung cancer	117	65(57–71)	85/32	Nivolumab 3 mg/kg every 14 days	2.3	8.0
Yamazaiki, 2017 [35]	2	Melanoma	24	63(26–81)	14/10	Nivolumab 3 mg/kg every 14 days	11.9(0.5–21.0)	18.8(2.0–21.5)
Younes, 2016 [36]	2	Hodgkin lymphoma	80	37(28–48)	51/29	Nivolumab 3 mg/kg every 14 days	8.5	8.9

Abbreviation: G/GJC gastric and gastro-esophageal junction cancer